Anemia of chronic kidney disease: CHOIR and the FDA

Nature Clinical Practice Nephrology

Volumn 3, Issue 8, 2007, Pages 406-407

  Singh, Ajay K ^a,b,c,d  

^a Renal Division   (United States)

^b Dialysis Services   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CRITICALLY ILL PATIENT; DEATH; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MULTIVARIATE ANALYSIS; POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; SPINE SURGERY; THROMBOSIS;

ANEMIA; CHRONIC DISEASE; HEMATOPOIESIS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34547229592     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0539     Document Type: Short Survey

References (11)

1. Singh AK et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098
2. US Food and Drug Administration (online 9 March 2007) Public Health Advisory: erythropoiesis-stimulating agents (ESAs) [http://www.fda.gov/cder/ drug/advisory/RHE2007.htm] (accessed 23 April 2007)
3. Besarab A et al. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590
4. Drueke TB et al. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084
5. Phrommintikul A et al. (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369: 381-388
6. Strippoli GF et al. (2007) Haemoglobin targets: we were wrong, time to move on. Lancet 369: 346-350
7. Levin A (2007) Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 22: 309-312
8. Collins AJ et al. (2001) Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473
9. Collins AJ et al. (2000) Impact of hematocrit on morbidity and mortality. Semin Nephrol 20: 345-349
10. Regidor DL et al. (2006) Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191
11. Mix TC et al. (2005) Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149: 408-413